{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:00:37Z","timestamp":1787162437045,"version":"build-2736575974"},"reference-count":110,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Department of Health and Human Services Substance Abuse and Mental Health Services Administration"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain & Palliative Care Pharmacotherapy"],"published-print":{"date-parts":[[2024,1,2]]},"DOI":"10.1080\/15360288.2023.2290565","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T13:48:10Z","timestamp":1702648090000},"page":"56-73","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Barriers and Best Practices on the Management of Opioid Use Disorder"],"prefix":"10.1080","volume":"38","author":[{"given":"Michelle","family":"Krichbaum","sequence":"first","affiliation":[{"name":"Clinical Manager\u2013Pain Management and Palliative Care, Baptist Health South Florida, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Medical Liaison, Novo Nordisk"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devada","family":"Singh-Franco","sequence":"additional","affiliation":[{"name":"Associate Professor, Pharmacy Practice, Nova Southeastern University, Health Professions Division, Barry and Judy Silverman College of Pharmacy, Fort Lauderdale, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"key":"e_1_3_2_2_1","volume-title":"Goldfrank\u2019s Toxicologic Emergencies, 11e","author":"Nelson LS","year":"2019","unstructured":"Nelson LS, Olsen D. Opioids. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. Goldfrank\u2019s Toxicologic Emergencies, 11e. New York, NY: McGraw-Hill; 2019. https:\/\/accesspharmacy.mhmedical.com. Accessed August 29, 2023."},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-42917-1_22"},{"key":"e_1_3_2_4_1","unstructured":"Substance Abuse and Mental Health Services Administration. 2022. Key Substance Use and Mental Health Indicators in the United States: Results from the 2021 National Survey on Drug Use and Health. (HHS Publication No. PEP22-07-01-005 NSDUH Series H-57). Center for Behavioral Health Statistics and Quality Substance Abuse and Mental Health Services Administration. https:\/\/www.samhsa.gov\/data\/report\/2021-nsduh-annual-national-report. Accessed August 29 2023."},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2019.04.019"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2022.2081923"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000002496"},{"key":"e_1_3_2_9_1","unstructured":"Centers for Disease Control and Prevention (CDC). Synthetic opioid overdose data. https:\/\/www.cdc.gov\/drugoverdose\/deaths\/synthetic\/index.html#print. Accessed January 10 2023."},{"key":"e_1_3_2_10_1","unstructured":"Centers for Disease Control and Prevention. Opioid data analysis and resources. https:\/\/www.cdc.gov\/opioids\/data\/analysis-resources.html. Accessed June 23 2023."},{"key":"e_1_3_2_11_1","unstructured":"Centers for Disease Control and Prevention. U.S. overdose deaths in 2021 increased half as much as in 2020 \u2013 but are still up 15%. National Center for Health Statistics. May 11 2022. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2022\/202205.htm#print. Accessed January 9 2023."},{"issue":"1","key":"e_1_3_2_12_1","first-page":"43","article-title":"Comparative analgesic potency of heroin and morphine in postoperative patients","volume":"136","author":"Reichle CW","year":"1962","unstructured":"Reichle CW, Smith GM, Gravenstein JS, Macris SG, Beecher HK. Comparative analgesic potency of heroin and morphine in postoperative patients. J Pharmacol Exp Ther. 1962;136(1):43\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2006.pto_233.x"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-7-199904060-00019"},{"key":"e_1_3_2_15_1","unstructured":"Ahmad FC Rossen LM Sutton P. Provisional drug overdose death counts. Atlanta GA: National Center for Health Statistics; 2023."},{"key":"e_1_3_2_16_1","unstructured":"Wide-Ranging Online Data for Epidemiologic Research (WONDER). Atlanta GA: CDC National Center for Health Statistics; 2022. http:\/\/wonder.cdc.gov."},{"key":"e_1_3_2_17_1","unstructured":"Centers for Disease Control and Prevention. Fentanyl Facts. https:\/\/www.cdc.gov\/stopoverdose\/fentanyl\/index.html#print. Accessed January 10 2023."},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6834a2"},{"key":"e_1_3_2_19_1","unstructured":"Lexicomp Online. Lexi-Drugs. Fentanyl. Waltham MA: UpToDate Inc. http:\/\/online.lexi.com. Accessed January 10 2023."},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.12.005"},{"key":"e_1_3_2_21_1","unstructured":"United States Drug Enforcement Administration (DEA). DEA Issues Carfentanil Warning to Police and Public. September 22 2016. https:\/\/www.dea.gov\/press-releases\/2016\/09\/22\/dea-issues-carfentanil-warning-police-and-public. Accessed January10 2023."},{"key":"e_1_3_2_22_1","unstructured":"Sufentanil [Package Insert]. Lake Forest IL: Akorn Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/019050s032lbl.pdf. Accessed June 22 2023."},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2021.08.001"},{"key":"e_1_3_2_24_1","unstructured":"Substance Abuse and Mental Health Services Administration. 2020. Medications for Opioid Use Disorder for Healthcare and Addiction Professionals Policymakers Patients and Families. Treatment Improvement Protocol TIP 63 (HHS Publication No. PEP20-02-01-006). Rockville MD: US Department of Health and Human Services. https:\/\/store.samhsa.gov\/product\/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document\/PEP20-02-01-006. Accessed January 10 2023."},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109398"},{"key":"e_1_3_2_26_1","unstructured":"Biden-Harris Administration Designates Fentanyl Combined with Xylazine as an Emerging Threat to the United States. https:\/\/www.whitehouse.gov\/ondcp\/briefing-room\/2023\/04\/12\/biden-harris-administration-designates-fentanyl-combined-with-xylazine-as-an-emerging-threat-to-the-united-states\/. Accessed July 21 2023."},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7226a4"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2022.306881"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28160"},{"key":"e_1_3_2_30_1","unstructured":"American Society of Addiction Medicine. National Practice Guideline. For the Treatment of Opioid Use Disorder. 2020 Focused Update. https:\/\/sitefinitystorage.blob.core.windows.net\/sitefinity-production-blobs\/docs\/default-source\/guidelines\/npg-jam-supplement.pdf?sfvrsn=a00a52c2_2. Accessed January 10 2023."},{"key":"e_1_3_2_31_1","unstructured":"Lexicomp Online. Lexi-Drugs. Naloxone. Waltham MA: UpToDate Inc. http:\/\/online.lexi.com. Accessed January 10 2023."},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.09.003"},{"key":"e_1_3_2_33_1","unstructured":"Narcan [Package Insert]. Plymouth Meeting PA: Adapt Pharma Inc.; August 2020. https:\/\/www.narcan.com\/wp-content\/uploads\/2022\/06\/Gen2-Prescribing-Information.pdf. Accessed January 10 2023."},{"key":"e_1_3_2_34_1","unstructured":"Kloxxado [Package Insert]. Columbus OH: Hikma Specialty USA Inc.; April 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212045s000lbl.pdf. Accessed January 10 2023."},{"key":"e_1_3_2_35_1","unstructured":"Zimhi [Package Insert]. San Diego CA: Adamis Pharmaceuticals Corporation; October 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212854s000lbl.pdf. Accessed January 11 2023."},{"key":"e_1_3_2_36_1","unstructured":"Opvee [Package Insert]. Santa Monica CA: Opiant Pharmaceuticals; May 2023. https:\/\/opvee.com\/wp-content\/uploads\/2023\/05\/Combined_USPI-Patient-Info-IFU_May-22-2023.pdf. Accessed June 19 2023."},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.256115"},{"key":"e_1_3_2_38_1","unstructured":"U.S. Department of Health and Human Services. Naloxone: The Opioid Reversal Drug That Saves Lives. How Healthcare Providers and Patients Can Better Utilize This Life-Saving Drug. https:\/\/www.hhs.gov\/opioids\/sites\/default\/files\/2018-12\/naloxone-coprescribing-guidance.pdf. Accessed January 11 2023."},{"key":"e_1_3_2_39_1","unstructured":"United States Food and Drug Administration (FDA). Drug Safety Communications. FDA Identifies Harm Reported from Sudden Discontinuation of Opioid Pain Medicines and Requires Label Changes to Guide Prescribers on Gradual Individualized Tapering. April 9 2019. https:\/\/www.fda.gov\/media\/122935\/download. Accessed January 11 2023."},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2018.11.032"},{"key":"e_1_3_2_41_1","unstructured":"Substance Abuse and Mental Health Services Administration. Use of Medication-Assisted Treatment in Emergency Departments. HHS Publication No. PEP21-PL-Guide-5. Rockville MD: National Mental Health and Substance Use Policy Laboratory. Substance Abuse and Mental Health Services Administration; 2021. https:\/\/store.samhsa.gov\/sites\/default\/files\/pep21-pl-guide-5.pdf. Accessed January 5 2023."},{"key":"e_1_3_2_42_1","unstructured":"Vivitrol [Package Insert]. Waltham MA: Alkermes Inc.; September 2022. https:\/\/www.vivitrol.com\/content\/pdfs\/prescribing-information.pdf. Accessed January 11 2023."},{"key":"e_1_3_2_43_1","unstructured":"Sublocade [Package Insert]. North Chesterfield VA: Indivior Inc.; August 2022. https:\/\/www.sublocade.com\/Content\/pdf\/prescribing-information.pdf. Accessed January 11 2023."},{"key":"e_1_3_2_44_1","unstructured":"Lexicomp Online. Lexi-Drugs. Methadone. Waltham MA: UpToDate Inc. http:\/\/online.lexi.com. Accessed January 11 2023."},{"key":"e_1_3_2_45_1","unstructured":"Suboxone [Package Insert]. North Chesterfield VA: Indivior Inc . June 2022. https:\/\/www.suboxone.com\/pdfs\/prescribing-information.pdf. Accessed January 17 2023."},{"key":"e_1_3_2_46_1","unstructured":"Zubsolv [Package Insert]. Morristown NJ: Orexo US Inc.; June 2022. https:\/\/www.suboxone.com\/pdfs\/prescribing-information.pdf. Accessed January 17 2023."},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2498"},{"key":"e_1_3_2_50_1","unstructured":"Lexicomp Online. Lexi-Drugs. Buprenorphine. Waltham MA: UpToDate Inc. http:\/\/online.lexi.com. Accessed January 11 2023."},{"key":"e_1_3_2_51_1","unstructured":"Brixadi [Package Insert]. Plymouth Meeting PA: Braeburn Inc.; May 2023. https:\/\/www.brixadi.com\/pdfs\/brixadi-prescribing-information.pdf. Accessed June 18 2023."},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S85951"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-019-00143-6"},{"key":"e_1_3_2_54_1","unstructured":"Lexicomp Online. Lexi-Drugs. Buprenorphine and Naloxone. Waltham MA: UpToDate Inc. http:\/\/online.lexi.com. Accessed January 11 2023."},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.549272"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0238-6"},{"key":"e_1_3_2_57_1","unstructured":"United States Food and Drug Administration (FDA). FDA Warns about Dental Problems with Buprenorphine Medicines Dissolved in the Mouth to Treat Opioid Use Disorder and Pain. January 12 2022. https:\/\/www.fda.gov\/media\/155352\/download. Accessed June 22 2023."},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.07.035"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001189"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0227"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3474"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.4561"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108147"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01032-7"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2021.0378"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/emp2.12289"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2021.1968421"},{"key":"e_1_3_2_68_1","unstructured":"Center for Addiction Medicine and Policy. Buprenorphine cross-tapering using a low-dose (microdosing) Strategy. Penn Medicine 2022. [updated September 2022. Available from https:\/\/penncamp.org\/wp-content\/uploads\/2023\/02\/Buprenorphine_Lowdose_induction_microdosing_Final_11.22-1.pdf."},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19095276"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2018.07.013"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2018.01.054"},{"key":"e_1_3_2_72_1","unstructured":"National Institute on Drug Abuse National Institutes of Health U.S. Department of Health and Human Services. Naloxone DrugFacts; 2022. https:\/\/nida.nih.gov\/publications\/drugfacts\/naloxone. Accessed June 16 2023."},{"key":"e_1_3_2_73_1","unstructured":"Substance Abuse and Mental Health Services Administration. Removal of DATA Waiver (X-Waiver) Requirement. January 12 2023. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/removal-data-waiver-requirement. Accessed January 13 2023."},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108729"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2019.06.016"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.1331"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.12.018"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.08.017"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2023.04.029"},{"key":"e_1_3_2_80_1","unstructured":"Actions of the March 15 2021 Virtual House of Delegates. American Pharmacists Association. https:\/\/www.pharmacist.com\/Portals\/0\/PDFS\/HOD\/March_15_2021_Virtual_HOD_Session_Actions_FINAL.pdf?ver=lxb_o_r0k5IG0UiHVosA_g%3d%3d. Accessed January 25 2023."},{"key":"e_1_3_2_81_1","unstructured":"American Medical Association. Increasing availability of naloxone H-95.932. https:\/\/policysearch.ama-assn.org\/policyfinder\/detail\/naloxone?uri=\/AMADoc\/HOD-95.932.xml. Accessed January 25 2023."},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1177\/08971900211064459"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19063156"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17373"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1177\/0897190020903573"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017712725"},{"key":"e_1_3_2_87_1","unstructured":"Mid-Level Practitioners Authorization by State. https:\/\/www.deadiversion.usdoj.gov\/drugreg\/practioners\/mlp_by_state.pdf. Accessed January 25 2022."},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1331\/JAPhA.2015.14177"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.03.006"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15353"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2208055"},{"key":"e_1_3_2_92_1","unstructured":"Centers for Disease Control and Prevention. Fentanyl Test Strips: A Harm Reduction Strategy. https:\/\/www.cdc.gov\/stopoverdose\/fentanyl\/fentanyl-test-strips.html#print. Accessed January 17 2023."},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-018-0276-0"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.5455\/jbh.20181023074620"},{"key":"e_1_3_2_95_1","unstructured":"United States Food and Drug Administration (FDA). FDA Approves First Over-the-Counter Naloxone Nasal Spray. March 29 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-over-counter-naloxone-nasal-spray. Accessed June 19 2023."},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15163"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2098"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.3390\/psychiatryint2040028"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.38807"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.24991"},{"key":"e_1_3_2_101_1","first-page":"e81","article-title":"ACOG committee opinion no. 711. Opioid use and opioid use disorder in pregnancy","volume":"130","author":"Committee on Obstetric Practice","year":"2017","unstructured":"Committee on Obstetric Practice. ACOG committee opinion no. 711. Opioid use and opioid use disorder in pregnancy. Opioid Gynecol. 2017;130:e81\u2013e94.","journal-title":"Opioid Gynecol"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2020.100179"},{"key":"e_1_3_2_104_1","unstructured":"Guttmacher Institute. Substance use during pregnancy. https:\/\/www.guttmacher.org\/state-policy\/explore\/substance-use-during-pregnancy. Accessed January 28 2023."},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/jmwh.13019"},{"key":"e_1_3_2_106_1","unstructured":"Substance Abuse and Mental Health Services Administration. Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants. HHS Publication No. (SMA) 18-5054. Rockville MD: Substance Abuse and Mental Health Services Administration; 2018. https:\/\/store.samhsa.gov\/sites\/default\/files\/d7\/priv\/sma18-5054.pdf. Accessed January 30 2023."},{"key":"e_1_3_2_107_1","unstructured":"Substance Abuse and Mental Health Services Administration. Screening and Treatment of Substance Use Disorders among Adolescents. Advisory. Publication No. PEP20-06-04-008; 2021. https:\/\/store.samhsa.gov\/sites\/default\/files\/pep20-06-04-008.pdf. Accessed January 16 2023."},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-2056C"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2020.12.129"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108407"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2020.03.005"},{"key":"e_1_3_2_112_1","unstructured":"DEA Announces Important Change to Registration Requirement. https:\/\/www.deadiversion.usdoj.gov\/pubs\/docs\/A-23-0020-Dear-Registrant-Letter-Signed.pdf. Accessed January 25 2023."}],"container-title":["Journal of Pain & Palliative Care Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/15360288.2023.2290565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T22:35:58Z","timestamp":1727217358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/15360288.2023.2290565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"alternative-id":["10.1080\/15360288.2023.2290565"],"URL":"https:\/\/doi.org\/10.1080\/15360288.2023.2290565","relation":{},"ISSN":["1536-0288","1536-0539"],"issn-type":[{"value":"1536-0288","type":"print"},{"value":"1536-0539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ippc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ippc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-07-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}